Advances in STING Pathway Modulation for Cancer and Immunotherapy: A Comprehensive Review of Preclinical and Clinical Studies (2020–2024)
Cancer Biotherapy and Radiopharmaceuticals · 01.12.2025 · 40 (10) · 733-767
DOI: 10.1177/10849785251362585 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, online erschienen am 04.08.2025. Verfasst von Rahaman Shaik und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmaceutical Education & Research, New Delhi, India. Hauptthemen laut MEDLINE: STING Protein, Immunotherapy, Neoplasms, cGAS-STING Signaling Pathway. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 246 Literaturangaben.
Abstract (Originalsprache)
In cancer immunotherapy, the stimulator of interferon genes (STING) pathway regulation has become a promising new approach, offering potential solutions to overcome limitations of current treatments. Recent advances have revealed intricate mechanisms of STING activation and regulation, leading to the development of novel small-molecule agonists with improved properties. Preclinical studies have shown that STING agonists can convert “cold” tumors to “hot” ones, enhancing immune cell infiltration and overcoming resistance to checkpoint inhibitors. Combination strategies, particularly with existing immunotherapies and conventional treatments, have demonstrated synergistic effects. Early clinical trials evaluating STING agonists, both as monotherapies and in combination with checkpoint inhibitors, have yielded promising results. More specific methods have been made possible by biomarker investigations, which have revealed light on mechanisms of action and possible response predictors. Indirect STING activation through ENPP1 inhibition has emerged as a novel strategy, offering more controlled antitumor immunity enhancement while minimizing systemic toxicity. Innovative delivery systems, including nanoparticles and exosome-based therapies, improve STING modulators’ therapeutic index. While challenges remain, including precise regulation of STING activation and managing immune-related adverse events, rapid progress suggests that STING-targeted therapies could become cornerstone treatments. By harnessing innate immunity and enhancing its interplay with adaptive responses, STING modulators offer a potentially more accessible, cost-effective, and broadly applicable approach to cancer immunotherapy, addressing many current treatment limitations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmaceutical Education & Research, New Delhi, India.
- Department of Pharmacology, St.Pauls College of Pharmacy, Hyderabad, India.
ORCID-Profile: Rahaman Shaik
Zitieren
APA
Shaik, R., Suthar, K., Balija, C., Aleem, S., Syeda, F. S., Syeda, S., & Begum, S. (2025). Advances in STING Pathway Modulation for Cancer and Immunotherapy: A Comprehensive Review of Preclinical and Clinical Studies (2020–2024). Cancer Biotherapy and Radiopharmaceuticals, 40(10), 733-767. https://doi.org/10.1177/10849785251362585
Vancouver
Shaik R, Suthar K, Balija C, Aleem S, Syeda FS, Syeda S, et al. Advances in STING Pathway Modulation for Cancer and Immunotherapy: A Comprehensive Review of Preclinical and Clinical Studies (2020–2024). Cancer Biotherapy and Radiopharmaceuticals. 2025;40(10):733-767. doi:10.1177/10849785251362585
BibTeX
@article{Shaik2025,
author = {Shaik, Rahaman and Suthar, Komal and Balija, Chandrika and Aleem, Shifa and Syeda, Fatima Sarwar and Syeda, Sana and Begum, Shireen},
title = {Advances in STING Pathway Modulation for Cancer and Immunotherapy: A Comprehensive Review of Preclinical and Clinical Studies (2020–2024)},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2025},
volume = {40},
number = {10},
pages = {733--767},
doi = {10.1177/10849785251362585}
}
EUVIMED